Carbon quantum dots (CQDs) represent a rapidly emerging class of nanomaterials with significant potential in biomedical applications due to their tunable fluorescence, high biocompatibility, and versatile functionalization. This review focuses on the recent progress in utilizing CQDs for drug delivery, bioimaging, biosensing, and cancer therapy. With their unique optical properties, such as tunable fluorescence, high quantum yield, and photostability, CQDs enable precise bioimaging and sensitive biosensing. Their small size, biocompatibility, and ease of surface functionalization allow for the development of targeted drug delivery systems, enhancing therapeutic precision and minimizing side effects. In cancer therapy, CQDs have shown potential in photodynamic and photothermal treatments by generating reactive oxygen species under light exposure, selectively targeting cancer cells while sparing healthy tissues. Furthermore, CQDs’ ability to penetrate biological barriers including the blood–brain barrier opens new possibilities for delivering therapeutic agents to hard‐to‐reach areas, such as tumors or diseased tissues. However, challenges such as optimizing synthesis, ensuring long‐term stability, and addressing safety concerns in biological environments remain critical hurdles. This review discusses current efforts to overcome these barriers and improve CQD performance in clinical settings, including scalable production methods and enhanced biocompatibility. As research progresses, CQDs are expected to play an important role in improving healthcare by offering more targeted treatment options and contributing to advancements in personalized medicine.

Fetal lung development is a crucial and complex process that lays the groundwork for postnatal respiratory health. However, disruptions in this delicate developmental journey can lead to fetal lung development disorders, impacting neonatal outcomes and potentially influencing health outcomes well into adulthood. Recent research has shed light on the intriguing association between fetal lung development disorders and the development of adult diseases. Understanding these links can provide valuable insights into the developmental origins of health and disease, paving the way for targeted preventive measures and clinical interventions. This review article aims to comprehensively explore the association of fetal lung development disorders with adult diseases. We delve into the stages of fetal lung development, examining key factors influencing fetal lung maturation. Subsequently, we investigate specific fetal lung development disorders, such as respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD), congenital diaphragmatic hernia (CDH), and other abnormalities. Furthermore, we explore the potential mechanisms underlying these associations, considering the role of epigenetic modifications, transgenerational effects, and intrauterine environmental factors. Additionally, we examine the epidemiological evidence and clinical findings linking fetal lung development disorders to adult respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and other respiratory ailments. This review provides valuable insights for healthcare professionals and researchers, guiding future investigations and shaping strategies for preventive interventions and long-term care.

Cancer immunotherapy has revolutionized cancer treatment by leveraging the immune system to target and eliminate tumor cells. Implantable biomaterials, such as hydrogels, sponges, scaffolds, implantable microdevice platforms, and macrobeads, offer localized and sustained release of immunomodulatory agents, improving the delivery of treatments such as immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies like CAR‐T cells. This review examines the emerging role of these biomaterials in modulating the tumor microenvironment, enhancing immune cell recruitment, and reducing systemic side effects, positioning them as significant tools for treating solid tumors. Recent advances in material engineering are also discussed, including the integration of bioactive molecules and real‐time therapeutic adjustments based on patient‐specific immune responses, which offer new potential in personalized cancer treatments. However, challenges such as biocompatibility, high production costs, variability in patient response, and the necessity of surgical manipulations remain key obstacles. Nonetheless, ongoing research and technological advancements are steadily addressing these issues, paving the way for more effective and accessible cancer immunotherapies. Overall, this review highlights the promise of implantable biomaterials overcoming the current limitations of cancer immunotherapy and expanding the scope of effective, targeted cancer treatments.

The prevention of blindness from glaucoma requires multiple treatments to lower intraocular pressure. Here, human contact lenses are modified with highly porous metal‐organic frameworks with sustained release of brimonidine for prolonged glaucoma treatment. Various metal‐organic frameworks were screened for their attachment to lenses, loading with brimonidine, and drug‐release properties. Optimized therapeutic ocular lenses conjugated with MIL‐101(Cr) frameworks maintain optical transparency and power. Coating of lenses with MIL‐101(Cr) nanoparticles reduced brimonidine washout with tears and ensured a gradual and localized release of the drug into the eyeball through the cornea. The hybrid lenses provided a 4.5‐fold better decrease in eye pressure, compared by area under the curve (AUC) value to a commercially available brimonidine tartrate solution. Therapeutic lenses did not induce any notable eye irritation or corneal damage in vivo. The newly developed hybrid lenses are expected to provide a robust platform for the therapy and prevention of various ocular diseases.

Reactive oxygen species (ROS) are chemically reactive oxygen derivatives which are capable of profoundly altering cellular pathways. Due to their ability to induce oxidative damage and damage cells, ROS have been explored as a promising avenue to combat cancer and treat pathogenic bacteria. Recent intersections in the development of nanotechnology and ROS-based therapeutics include engineered nanoparticles, enzyme-mimicking nanozymes, and metal-organic frameworks. These nanoplatforms allow refined control of spatiotemporal generation of ROS within desired tissue, improved ROS targeting of cancer lesions and at sites of bacterial infection, and concurrent delivery of ROS-incorporated, multi-therapeutic agents. In this review, we outline the fundamental principles and advancements of ROS-based nanotherapies that have been used against both malignant cells and pathogenic bacteria, including photodynamic, sonodynamic, chemodynamic, and radiotherapeutic approaches. In addition, we explore strategies that combine ROS with immunotherapy or antibiotics to elicit synergistic anti-cancer or antimicrobial effects. Although ROS-based therapies face challenges in the current landscape, including limited tissue penetration, toxicity, and difficulties with in vivo monitoring, there are ongoing efforts to address these hurdles. Once a better mechanistic understanding of ROS is established and key biosafety criteria are met, once these challenges are addressed, ROS-based nanotherapies can serve as a powerful tool against tumors and drug-resistant bacteria, enable more effective personalized treatments, and advance precision medicine.